AsianScientist (May 6, 2013) – Tokyo, Japan-based Eisai Co., Ltd. announced this week that it will open a new plant at the Suzhou Industrial Park in Suzhou, Jiangsu, China, on a lot retained by Eisai’s Chinese subsidiary, Eisai China Inc.
Eisai currently retains a production facility near the site of the new plant, as a solid preparation production and packaging base that supplies domestic demand in China.
Its decision to establish the new facility is aimed at constructing a stable supply chain for injection products in China in expectation of future sustained growth in the Chinese pharmaceutical market, particularly a forecasted increase in demand for Methycobal® injection, one of Eisai’s major products in China, as a drug for peripheral neuropathies.
The move is also expected to achieve cost reduction at the new plant through improving production efficiency in the mid-term. Injection products produced at the new plant will also be considered for supply to emerging countries, including in Asia and Central and South America, with the goal of having the new plant function as a global supply base.
The new plant will be built on an approximately 132,000 square meters lot purchased by Eisai in 2010. The facility will stand two floors above ground, contain a building area of approximately 2,500 square meters, and initially operate as a production line of Methycobal injection.
Construction is planned for commencement in the third quarter of fiscal 2013 and completion in the first half of fiscal 2014.
——
Source: Eisai.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
